



## King's Research Portal

DOI:

[10.1111/hiv.12598](https://doi.org/10.1111/hiv.12598)

[10.1111/hiv.12598](https://doi.org/10.1111/hiv.12598)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Haynes, B. I., Pitkänen, M., Kulasegaram, R., Casey, S. J., Schutte, M., Towgood, K., Peters, B. S., Barker, G. J., & Kopelman, M. D. (2018). HIV: ageing, cognition and neuroimaging at 4 year follow-up. *HIV MEDICINE*.  
<https://doi.org/10.1111/hiv.12598>, <https://doi.org/10.1111/hiv.12598>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

This is the peer reviewed version of the following article:

Article ID: HIV12598

Article DOI: 10.1111/hiv.12598

Internal Article ID: 14907660

Article: Human Immunodeficiency Virus: ageing, cognition and neuroimaging at 4 year follow-up.

Journal: HIV Medicine

which has been published in final form at <https://doi.org/10.1111/hiv.12598>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Human Immunodeficiency Virus: ageing, cognition and neuroimaging at 4 year follow-up.

Haynes, B.I<sup>1</sup>, Pitkanen, M.<sup>1 2</sup>, Kulasegaram, R.<sup>3</sup>, Casey, S.J<sup>1</sup>, Schutte, M.<sup>1</sup>, Towgood, K.<sup>1</sup>, Peters, B. <sup>1 2</sup>, Barker, G.J.<sup>1</sup>, & Kopelman, M.D. <sup>1 2</sup>.

<sup>1</sup> Kings College London, Institute of Psychiatry, Psychology & Neurosciences, London, SE1 7EH, UK.

<sup>2</sup> South London and Maudsley NHS Trust, based at St Thomas' Hospital, London SE1 7EH.

<sup>3</sup> Guy's and St Thomas' NHS Trust, St Thomas' Hospital, London SE1 7EH,

Corresponding Authors:

Dr Rebecca Haynes, [beckyilanahaynes@gmail.com](mailto:beckyilanahaynes@gmail.com)

or Prof M.D. Kopelman, [michael.kopelman@kcl.ac.uk](mailto:michael.kopelman@kcl.ac.uk)

Requests for reprints should be directed to Prof M.D. Kopelman,

[michael.kopelman@kcl.ac.uk](mailto:michael.kopelman@kcl.ac.uk)

Running head: HIV ageing, cognition and neuroimaging.

Keywords: Ageing; Cognition; HIV; Neuroimaging; Longitudinal

## Abstract

**Objective:** To investigate the hypothesis of accelerated cognitive ageing in HIV positive individuals using longitudinal assessment of cognitive performance and quantitative MRI.

**Methods:** We assessed a broad cognitive battery and quantitative MRI metrics (voxel based morphometry: VBM and diffusion tensor imaging: DTI) in asymptomatic HIV positive men who have sex with men (15 aged 20-40 years and 15 aged  $\geq 50$  years), and seronegative matched controls (nine aged 20-40 years and 16 aged  $\geq 50$  years).

**Results:** Being HIV positive was associated with a greater decrease in executive function, and global cognition. Additionally, using DTI, the HIV Group had a greater increase in mean diffusivity, but we did not find group differences on volume change using VBM. With respect to the HIV by Age Group interaction, this was **statistically** significant for change in global cognition, with older HIV positive individuals showing greater global cognitive decline, but there were no significant interactions on other measures. Lastly, change in cognitive performance was correlated with change in the DTI measures, and this effect was stronger for the HIV positive participants.

**Conclusions:** **In the present study, we found some** evidence for accelerated ageing in HIV with a **statistically** significant HIV by Age Group interaction in global cognition, although this interaction could not be explained by the imaging findings. Moreover, we also found that change in cognitive performance correlated with change in the DTI measures, and this effect was stronger for the HIV positive participants. **This will need replication in larger studies using a similar follow-up delay.**

*Keywords* Ageing; Cognition; HIV; Neuroimaging; Longitudinal

## Introduction

Human Immunodeficiency Virus-1 (HIV-1) infection is characterized by inflammation of the CNS (1). Following the introduction of Highly Active Antiretroviral Therapy (HAART) the prognosis of HIV positive individuals in terms of morbidity and mortality has greatly improved (2). However, a substantial proportion of patients report mild cognitive problems, despite being on treatment (for review, see 3), with reported prevalence of HIV associated neurocognitive disorders in 30 to 50% of individuals (4, 5). This suggests the possibility that there is HIV related neuronal damage even in the subclinical stages of infection in people who are on stable HAART.

With improved survival following HIV infection, one in four individuals living with HIV in the United Kingdom is now aged 50 or over (6). The combined influence of ageing and HIV is an important research area as there is evidence that HIV infection is associated with a higher prevalence of age-related conditions at a younger age (7). Moreover, it has been suggested that older age is associated with an increased risk of HIV associated neurocognitive disorders (8-10), indicating a possible effect of accelerated neurocognitive ageing (see 11). This was addressed in a recent review of behavioural and neuroimaging studies published between 2011 and 2014 (12). This revealed mixed findings, with 11 studies (six behavioural, five neuroimaging) supportive of the accelerated ageing hypothesis in HIV, and nine studies (four behavioural, five neuroimaging) not supportive. The authors suggested that methodological differences could explain the discrepancies, with studies that used global cognitive measures or neuroimaging techniques with poor specificity were less likely to find an interaction between HIV and age. However, as the majority (19 out of 20) of these studies were cross-sectional, this limits the extent to which accelerated neurocognitive ageing can be ascertained.

There have been fewer longitudinal studies that have investigated the impact of age and HIV on change in cognitive performance, but there is evidence for interacting effects of HIV and ageing. In one study, older HIV positive individuals showed a greater decline in executive function over five years than younger HIV positive individuals, whereas there was no effect of age on longitudinal performance for the seronegative controls (13). Similarly, individuals with HIV showed a greater one-year decline in verbal memory with increasing age, whereas the seronegative controls showed stable or improved performance with age (14). However, other longitudinal studies have not found interactive effects between HIV and age on cognitive change. For example, although HIV infection was associated with faster rates of cognitive decline in executive function, there was no evidence for accelerated decline with older age (15); and age was not a predictor of cognitive decline in a HIV cohort assessed regularly for up to five years (16). Instead, change in cognitive status was associated with disease severity, race, premorbid intelligence, current depressive symptoms, lifetime psychiatric diagnoses, and non-HIV-related comorbidities. Although this latter study highlighted the multifaceted risk factors for cognitive decline in HIV infection, it did not determine the degree to which HIV itself is linked to cognitive change in the absence of other risk factors.

MRI studies have further explored the impact of prolonged HIV exposure on brain structure. One such study found a greater increase in mean diffusivity (MD) in HIV positive individuals compared with seronegative controls, however the influence of age on HIV associated change in MD was not explored. The trajectories of volume change in HIV positive individuals and healthy controls have also been investigated (15). Here, the HIV group showed significantly greater change per year of infection than controls in terms of hippocampal and insula atrophy and significantly increased lateral ventricle volumes. There

was also significant acceleration of age-related trajectories of grey matter volume change in the thalamus and frontal, sensorimotor, and temporo-parietal neocortical regions.

In a previous study (17), we examined HIV positive and HIV negative older and younger individuals. All participants were asymptomatic with undetectable HIV viral loads, without medical or psychiatric comorbidity, or alcohol or substance misuse, and they had all been stable on HAART for at least six months prior to enrolment in the study. Comparison of the HIV groups did not show significant differences on the neuropsychological tests after Bonferroni correction. However, we found reduced grey matter volume on MRI in our HIV-positive participants. Moreover, on FDG-PET and MRI based arterial spin labelling, (18) we found age-related reductions in the metabolic rate of glucose consumption and cerebral blood flow in frontal brain regions, and consistent (although small) reductions in the anterior cingulate in HIV. Across all measures, there were no significant HIV by Age Group interactions.

In the present study, we re-assessed these participants, extending previous longitudinal investigations in the following ways: (i) all were on HAART, and all had undetectable viral load at baseline; (ii) all were Caucasian men who have sex with men; (iii) other confounding variables were controlled; and (iv) mean follow-up duration was 4.2 years. We investigated the interaction of HIV and age upon individual cognitive domains and global cognitive performance and we related these findings to concurrent MRI measures to see whether any cognitive deterioration was accompanied by associated changes in structural brain metrics. We hypothesised that:

- (i) There would be significant HIV by Age Group interaction in terms of change scores on cognitive testing;
- (ii) There would be significant HIV by Age Group interaction in terms of change in neuroimaging indexes;

- (iii) There would be significant correlations between cognitive and neuroimaging changes.

## **Methods**

### **Participant population**

Fifty-five participants (67%) from our previous cross-sectional study (17, 18) were included in the present study, with a mean time between assessments of 4.2 years ( $SD=0.8$ ). Informed consent was obtained from all participants according to the Declaration of Helsinki and the study was approved by the East London Research Ethics Committee 3, NHS research ethics committee (Ref. 11/LO/0037).

All participants were Caucasian and self-identified as ‘men who have sex with men’. Baseline exclusion criteria were hepatitis B or C infection, any confounding neurological disorder, a history of head trauma with loss of consciousness greater than 10 minutes, and a history of harmful alcohol (>25 units of alcohol per week) or substance misuse. Additionally, the HIV positive participants were stable on HAART with an undetectable viral load (< 50 copies/mL) and did not have a current or previous CNS-AIDS-condition. These criteria were met at follow-up, though one HIV positive individual reported harmful alcohol use and another had a viral load of 147 copies per mL. Excluding these two individuals did not influence the interpretation of any results; therefore, analyses based on the full sample have been reported.

### **Medical and psychiatric evaluation**

Participants underwent a brief medical assessment and routine blood investigations which included HIV viral load, CD4 count (HIV group), conformation of HIV-negative status (control group), syphilis screen, hepatitis B and C, renal and liver function tests, bone and lipid profiles, and vitamin B12. The Beck Depression Inventory (19) and Beck Anxiety



Inventory (20), Profile of Mood States (McNair et al., 1981) were be used to assess mood state. The frequency of perceived memory difficulties was evaluated using the Prospective and Retrospective Memory Questionnaire (21).

### **Cognitive assessment**

A wide range of cognitive tests was administered by trained psychologists (SC and BH) using standardised procedures. Raw scores were converted to z-scores using baseline seronegative findings, which were then averaged to form five cognitive domain scores; executive function, complex attention, learning and memory, language, and perceptual motor function. The tasks that were included in each domain can be found in Table 1. Change scores were generated by subtracting the baseline from follow-up z-scores.

Table 1 about here

### **MRI protocol**

Scans were acquired on a GE SIGNA 3T MR scanner (General Electric, Chicago, USA) at the Centre for Neuroimaging Sciences, King's College London using the same imaging protocol as the baseline study (17).

### **Image processing**

**Voxel-based morphometry (VBM) processing.** Datasets were pre-processed and analysed using SPM12 (Wellcome Department of Cognitive Neurology, London, UK, <http://fil.ion.ucl.ac.uk>). As the original study used XBAM (22), we first reanalysed the baseline data using the DARTEL toolbox (23, 24) in SPM12 to confirm that results were consistent with those previously reported (17).

**Longitudinal VBM analysis.** Baseline and follow-up scans were submitted to a pairwise longitudinal registration (25) using SPM12. This procedure generates normalised images of grey matter volume loss between scan 1 and scan 2. These images were then used for statistical analysis in which a two-way (HIV status by Age Group) ANOVA was fitted at

each voxel in standard space. Further detail of the analysis procedure can be found in the Supplemental Digital Content.

**Diffusion Tensor Imaging (DTI) analysis.** Datasets were pre-processed and analysed using tools from the Oxford Centre for Functional MRI of the Brain Software Library (FSL; <http://www.fmrib.ox.ac.uk/fsl>). One older control was excluded following manual inspection for artefacts. Pre-processing used a standard multi-step procedure that involved correction for motion and eddy-currents (26), extraction of non-brain tissue (27), and fitting a tensor model to the raw diffusion weighted images. Maps of the directionality (Fractional anisotropy: FA) and the extent (MD) of diffusion were then generated. As the present analysis method differed from that used at baseline (XBAM; 22), we first reanalysed the baseline scans using tract based spatial statistics (TBSS; 28). The results were consistent with those reported in the original paper (17).

**Longitudinal DTI analysis.** Longitudinal effects were analysed using a modified longitudinal TBSS protocol based on (29), which was designed to optimise intra-subject registration and account for residual variation due to change of head placement and MRI scanner drift between sessions. This protocol produced skeletonised maps of the difference in FA or MD between the two scans. Further detail of the analysis procedure can be found in the Supplemental Digital Content. Analysis was performed using permutation-based nonparametric cluster inference (Randomise, implemented in FSL). A two-way (HIV status by Age Group) ANCOVA was applied using 10,000 permutations with time between scans added as a covariate. For each statistical test, results were corrected for multiple comparisons using Threshold-Free Cluster Enhancement (TFCE; 30).

## **Results**

### **Clinical and psychiatric evaluation**

Table 2 shows the characteristics of study participants. The younger HIV positive participants were significantly older than the younger seronegative group. No other differences were evident between these younger groups. Similarly the older HIV positive participants did not differ from the older seronegative group. In particular, there were no group differences on anxiety or depression measures in either the younger or older participants. Looking at HIV-related variables, the older and younger HIV positive individuals did not differ significantly on current  $t(30)=0.43, p=.673, d=0.16$  or nadir  $t(28)=0.49, p=.628, d=0.19$  CD4 count. The older HIV participants had a longer average number of years since diagnosis than the younger participants  $t(28)=3.26, p=.003, d=1.19$ , but treatment duration did not reach statistical significance,  $t(28)=1.97, p=.059, d=0.72$ .

Table 2 approx here

### **Group difference analysis for the neuropsychological assessment**

**HIV status.** There was a statistically significant effect of HIV status on change in executive function  $F(1,55)=6.77, p=.012, d=0.70$  and global cognition,  $F(1,55)=7.89, p=.007, d=.76$ . The results suggest that the HIV group (executive function,  $M= -0.40, SD=0.75$ ; global cognition,  $M= -0.12, SD=0.33$ ) displayed a greater reduction in z-scores than the seronegative controls (executive function,  $M=0.06, SD=0.44$ ; global cognition,  $M=0.08, SD=0.19$ ). Differences were non-significant for the other cognitive domains; in each of these,  $F(1,55)\leq 2.71, p\geq .106, d\leq 0.45$ .

**Age.** There was a statistically significant effect of Age Group on change in complex attention,  $F(1,55)=6.70, p=.011, d=0.72$ , perceptual-motor function,  $F(1,55)=5.83, p=.020, d=0.66$  and global cognition,  $F(1,55)=6.21, p=.016, d=0.68$ . Here, the older participants showed a greater reduction in z-scores than the younger participants. The effect of age was not significant for the other cognitive domains, in each of these  $F(1,55)\leq 2.41, p\geq .127$ ,

$d \leq 0.36$ . Critically, this included executive function, which was the only domain to show an effect of HIV status.

**HIV status by Age Group interaction.** One important question was whether the results were suggestive of accelerated ageing with HIV. Here, we were interested in whether there was a significant HIV by Age Group interaction. This was only significant for change in global cognition,  $F(1,55)=4.39$ ,  $p=.041$ , where there was a larger difference in global change scores between the older HIV positive and negative participants,  $t(31)=3.25$ ,  $p=.003$ ,  $d=1.17$  than the younger participants,  $t(24)=0.54$ ,  $p=.598$ ,  $d=0.23$ . These cognitive findings are summarised in Figure 1.

Figure 1 approx here

## Neuroimaging findings

**HIV status.** Using VBM, no regions reached family-wise error corrected significance for the main effect of HIV status on rate of grey matter volume change. On the DTI metrics, there was no significant main effect of HIV status on change in FA. There was, however, a significant difference for change in MD, with the HIV group showing a greater increase in MD than the seronegative controls in the corpus callosum, the right posterior corona radiata and right posterior thalamic radiation (see Figure 2).

Figure 2 approx here

**Age.** On the VBM analysis, there was no effect of age on rate of change in regional grey matter volume (family-wise error corrected  $p < .05$ ). With respect to the DTI measures, older participants showed a greater decrease in FA than the younger group in the right anterior corona radiata, right anterior limb of the internal capsule, and the right genu and splenium of the corpus callosum. There were also significant age effects on change MD, in widespread regions bilaterally (See Figure 3).

Figure 3 approx here

**HIV status by Age Group interaction.** No significant interactions were identified between HIV status and age group for change in grey matter volume, change in FA, or change in MD.

**Correlations between HIV, neuroimaging, and neuropsychological variables.**

To allow comparison between the neuropsychological and neuroimaging variables, atlas-based regions of interest (frontal white matter and the genu, body, and splenium of the corpus callosum) were created in FSL using the JHU ICBM-DTI-81 White-Matter Labels Atlas (<http://cmrm.med.jhmi.edu>). FA and MD values were extracted from the baseline and follow-up scans and were then subtracted to generate  $FA_{DIFF}$  and  $MD_{DIFF}$  scores.

A series of hierarchical multiple regression models were used to explore the influence of HIV status and  $FA_{DIFF}$  or  $MD_{DIFF}$  on global cognitive change. Step 1 adjusted for covariates of age group, IQ, and time between assessments. At Step 2, the primary effects of HIV status and  $FA_{DIFF}$  or  $MD_{DIFF}$  were added, and at Step 3, a HIV status x  $FA_{DIFF}$  /  $MD_{DIFF}$  cross-product interaction term was entered. Here, we were interested in whether the interaction term significantly added to the variance ( $\Delta r^2$ ) explained in global cognitive change, which would suggest the strength of the association between change in the DTI metrics and change in cognition varied as a function of HIV status.

The results of the hierarchical regressions can be found in Table 3. Adding HIV status and  $FA_{DIFF}$  or  $MD_{DIFF}$  added to the prediction of global cognitive change, with shared variances ranging from 26 to 37%. Importantly, at Step 3, the HIV status x  $FA_{DIFF}$  or HIV x  $MD_{DIFF}$  interaction terms were significant for the majority of regions (all except  $FA_{DIFF}$  in the body of the corpus callosum). The interaction explained a further 7 to 15% of the variance in global cognitive change. This association was further explored separately in the patient and control groups. In the HIV group, worsening cognitive performance was associated with a greater increase in MD ( $\beta \leq -.531$ ,  $p < .01$ ) and a greater decrease in FA ( $\beta \geq .483$ ,  $p < .01$ ),

whereas these relationships were of a smaller magnitude and were non-significant in the seronegative group (MD,  $\beta \geq -.214$ ,  $p \geq .442$ ; FA,  $\beta \leq .429$ ,  $p \geq .060$ ). Lastly, in the HIV positive participants we assessed whether the association between change in DTI metrics and change in cognitive performance was modified by age group. The Age by DTI metric cross-product interaction was non-significant for all measures.

Table 3 approx here

## Discussion

This study investigated longitudinal change in cognitive performance and quantitative MRI findings in HIV positive individuals. We hypothesised that there would be an interaction between age group and HIV status, supporting the notion of accelerated ageing in HIV (11). In our small sample, we found that the HIV positive participants had a greater global cognitive decline than their seronegative controls and this was exacerbated in the older age group. However, when the cognitive domains were analysed separately, there were no significant HIV by Age Group interactions. On neuroimaging measures, HIV infection and older age were each associated with a greater increase in MD, but there were no significant HIV by Age Group interactions. Lastly, change in cognitive performance correlated with change in DTI measures, and this effect was stronger for the HIV positive participants but did not differ between the age groups.

It is of note that HIV and Age Group appeared to affect different components of cognitive function. There was a statistically significant effect of HIV on executive function, whereas age group influenced domains that involved speed of performance (i.e., change in complex attention and perceptual-motor function). With respect to executive function, younger HIV positive individuals, as well as older ones, showed worse performance (in terms of change scores), relative to controls. This suggests it was HIV infection itself that

influenced this domain rather than an effect of age group. While the present results are broadly consistent with previous neuropsychological findings (e.g., 15), we must acknowledge that caution is needed in interpreting these cognitive findings because of the small sample size in our groups.

The VBM results showed no influence of HIV or age group on grey matter volume, and no interaction between HIV status and age group, suggesting that the groups showed an equivalent rate of change in volume over time. At baseline, we found reduced grey matter volume in a cluster encompassing the medial and superior frontal-gyrus in the HIV positive participants (17). Longitudinally, we did not find evidence that this had progressed (although this might perhaps have reflected the relatively young age of our older group, with a minimum age of 50 years at baseline). One possible interpretation of this particular finding would be that HIV has an effect on grey matter volume early in the disease process, for example pre-treatment. By contrast, one previous study (15) did find evidence of HIV by Age effects on regional grey matter in a sample which was larger than ours, but less highly selected to exclude confounding factors.

Our DTI findings highlighted the importance of longitudinal evaluation in HIV, as baseline analysis in this sample did not find any differences on either MD or FA (17), but in the present analysis, we found that both HIV infection and age group were associated with a greater longitudinal increase in MD. In other words, HIV infection was associated with greater cerebral white matter damage through time, even in patients who had a good treatment response to HAART and no significant cerebrovascular risk factors. This may reflect persistent immune activation and neuro-inflammation (31, 32). The present results also suggest that the group differences in DTI change scores might be clinically relevant, as regression analysis indicated that cognitive performance changed in conjunction with DTI change, and that this association was stronger for the HIV group. Thus, the HIV positive

patients with the greatest increase in MD, or decrease in FA, showed the greatest decline in cognitive performance (in terms of change scores). There have been few other longitudinal DTI studies in persons with HIV, but our results are in line with a previous study that showed an HIV related increase in MD in the genu of the corpus callosum and a correlation between change in global cognition and DTI measures in the corpus callosum in HIV positive individuals (33). We have extended this from one year to a longer follow-up duration and using voxel-based procedures, we identified more widespread longitudinal changes. We also showed that older age was associated with a greater increase in MD and decrease in FA. However, in the present sample, there were no HIV by age group interactions, and similar DTI-cognitive associations were evident in both the younger and older HIV positive participants.

Our study had a number of strengths. It had a relatively long follow-up, with a mean duration of 4.2 years. It was well controlled in terms of comorbidities, and drug and alcohol use, and the HIV positive group was asymptomatic and stable on HAART. We also carefully recruited a control group with a similar sociodemographic background who were well matched on age, IQ, and education. We can, therefore, be confident that the findings are likely to be the result of HIV infection and not of other confounding factors. There were, however, some limitations. Sample sizes were relatively small as we were limited by the size of the original sample. Moreover, the detail of our neuropsychological assessment, the range of our imaging protocols (which included positron emission tomography at baseline), and the duration of our follow-up, may have affected the attrition rate, which was imbalanced across the groups. The findings should be corroborated in larger samples, allowing for variability in other important factors that can affect cognition such as anxiety and depression scores.

In conclusion, we found independent (main) effects of both HIV and age group on longitudinal change in cognitive performance and change through time in mean diffusivity



using DTI, but not an effect on volumetrics. The results suggested accelerated ageing in HIV, in that there was a significant HIV by Age Group interaction for change in global cognition. Being HIV positive and older was associated with a worsening in overall cognitive performance. However, this interaction could not be explained by the imaging findings, as there were no significant interactions for any of the imaging metrics. Further work is needed to look at other biological factors that could explain change in overall cognitive performance in HIV, including metabolic findings and treatment effects.

## **Acknowledgements**

This research was supported by grants from the Guy's and St Thomas's Charity (R090767, R041051). We would like to thank the staff from the Harrison Wing, Guys and St Thomas's NHS Foundation Trust for their support in the project.

## References

1. Spudich S, Gisslen M, Hagberg L, et al. Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. *J Infect Dis*. 2011;204(5):753-60.
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. *Lancet*. 2008;372(9635):293-9.
3. Schouten J, Cinque P, Gisslen M, et al. HIV-1 infection and cognitive impairment in the cART era: a review. *Aids*. 2011;25(5):561-75.
4. Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study. *Neurology*. 2010;75(23):2087-96.
5. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. *J Neurovirol*. 2002;8(2):136-42.
6. Public Health England. HIV in the United Kingdom: 2014 Report 2014 [Sept 2016]. Available from: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/401662/2014\\_PHE\\_HIV\\_annual\\_report\\_draft\\_Final\\_07-01-2015.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/401662/2014_PHE_HIV_annual_report_draft_Final_07-01-2015.pdf).
7. Guaraldi G, Orlando G, Zona S, et al. Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population. *Clinical Infectious Diseases*. 2011;53(11):1120-6.

8. Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals - The Hawaii Aging with HIV-1 Cohort. *Neurology*. 2004;63(5):822-7.
9. Wendelken LA, Valcour V. Impact of HIV and aging on neuropsychological function. *J Neurovirol*. 2012;18(4):256-63.
10. Becker JT, Lopez OL, Dew MA, Aizenstein HJ. Prevalence of cognitive disorders differs as a function of age in HIV virus infection. *Aids*. 2004;18:S11-S8.
11. Cohen RA, Seider TR, Navia B. HIV effects on age-associated neurocognitive dysfunction: premature cognitive aging or neurodegenerative disease? *Alzheimer's research & therapy*. 2015;7(1):37.
12. Cysique LA, Brew BJ. The effects of HIV and aging on brain functions: proposing a research framework and update on last 3 years' findings. *Curr Opin HIV Aids*. 2014;9(4):355-64.
13. Sacktor N, Skolasky RL, Cox C, et al. Longitudinal psychomotor speed performance in human immunodeficiency virus-seropositive individuals: impact of age and serostatus. *J Neurovirol*. 2010;16(5):335-41.
14. Seider TR, Luo X, Gongvatana A, et al. Verbal memory declines more rapidly with age in HIV infected versus uninfected adults. *J Clin Exp Neuropsych*. 2014;36(4):356-67.
15. Pfefferbaum A, Rogosa DA, Rosenbloom MJ, et al. Accelerated aging of selective brain structures in human immunodeficiency virus infection: a controlled, longitudinal magnetic resonance imaging study. *Neurobiol Aging*. 2014;35(7):1755-68.

16. Heaton RK, Franklin DR, Jr., Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. *Clin Infect Dis.* 2015;60(3):473-80.
17. Towgood KJ, Pitkanen M, Kulasegaram R, et al. Mapping the brain in younger and older asymptomatic HIV-1 men: Frontal volume changes in the absence of other cortical or diffusion tensor abnormalities. *Cortex.* 2012;48(2):230-41.
18. Towgood KJ, Pitkanen M, Kulasegaram R, et al. Regional cerebral blood flow and FDG uptake in asymptomatic HIV-1 men. *Hum Brain Mapp.* 2013;34(10):2484-93.
19. Beck AT. Beck Depression Inventory. San Antonio: The Psychological Corporation; 1987.
20. Beck AT, Steer RA. Beck Anxiety Inventory. San Antonio, TX: The Psychological Corporation; 1990.
21. Smith G, Della Sala S, Logie RH, Maylor EA. Prospective and retrospective memory in normal ageing and dementia: A questionnaire study. *Memory.* 2000;8(5):311-21.
22. Bullmore ET, Suckling J, Overmeyer S, Rabe-Hesketh S, Taylor E, Brammer MJ. Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain. *IEEE Trans Med Imaging.* 1999;18(1):32-42.
23. Ashburner J. A fast diffeomorphic image registration algorithm. *NeuroImage.* 2007;38(1):95-113.
24. Ashburner J. VBM Tutorial. (Manual). 2010 [Sept 2016]. Available from: <http://www.fil.ion.ucl.ac.uk/~john/misc/VBMclass10.pdf>.

25. Ashburner J, Ridgway GR. Symmetric diffeomorphic modeling of longitudinal structural MRI. *Front Neurosci.* 2012;6:197.
26. Jenkinson M, Smith SM. A global optimisation method for robust affine registration of brain images. *Medical image analysis.* 2001;5(2):143-56.
27. Smith SM. Fast robust automated brain extraction. *Hum Brain Mapp.* 2002;17(3):143-55.
28. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. *NeuroImage.* 2006;31(4):1487-505.
29. Engvig A, Fjell AM, Westlye LT, et al. Memory training impacts short-term changes in aging white matter: A Longitudinal Diffusion Tensor Imaging Study. *Hum Brain Mapp.* 2012;33(10):2390-406.
30. Smith SM, Nichols TE. Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference. *NeuroImage.* 2009;44(1):83-98.
31. Anthony IC, Bell JE. The Neuropathology of HIV/AIDS. *Int Rev Psychiatry.* 2008;20(1):15-24.
32. Anzinger JJ, Butterfield TR, Angelovich TA, Crowe SM, Palmer CS. Monocytes as Regulators of Inflammation and HIV-Related Comorbidities during cART. *J Immunol Res.* 2014.
33. Chang LD, Wong V, Nakama H, et al. Greater Than Age-Related Changes in Brain Diffusion of HIV Patients After 1 Year. *J Neuroimmune Pharm.* 2008;3(4):265-74.

34. Reitan R, Wolfson D. The Halstead-Reitan neuropsychology test battery. Tuscon: Neuropsychological Press; 1988.
35. Nelson HE. A modified card sorting test sensitive to frontal lobe defects. *Cortex*. 1976;12(4):313-24.
36. Gronwall D, Sampson H. The psychological effects of concussion. Auckland, New Zealand: Auckland University Press; 1974.
37. Weschler D. Wechsler Adult Intelligence Scale – Third Edition: Administration and Scoring Manual. London, UK: The Psychological Corporation; 1997.
38. Weschler D. Wechsler Memory Scale – Revised. San Antonio, USA: he Psychological Corporation; 1987.
39. Rey A. L'Examen Clinique en Psychologie Paris, France: Press Universitaire de France.; 1964.
40. McKenna P, Warrington EK. Testing for nominal dysphasia. *J Neurol Neurosurg Psychiatry*. 1980;43(9):781-8.
41. Castel AD, Craik FI. The effects of aging and divided attention on memory for item and associative information. *IEEE Trans Med Imaging Psychology and aging*. 2003;18(4):873-85.
42. Benton AL. Differential Behavioral Effects in Frontal Lobe Disease. *Neuropsychologia*. 1968;6(1):53-&.
43. Lafayette Instruments. Grooved Pegboard Test: User Instructions. Lafayette, IN, USA: Lafayette Instrument Company; 2002.

44. Jenkinson M, Smith SM. A global optimisation method for robust affine registration of brain images. *Medical image analysis* 2001; 5(2): 143-56.

Table 1: The cognitive test battery

<b>Executive function</b>	<b>Complex attention</b>
Trail Making Test B (34),	Trail Making Test A (34)
Modified Cord Sorting Test (35),	Paced Serial Addition Test (36)
WAIS III Letter number sequencing (37)	WAIS III Symbol search (37)
WAIS III Matrix reasoning (37)	WAIS III Digit span (37)
	WAIS III Digit-symbol coding (37)
<b>Learning and memory</b>	<b>Language</b>
WAIS-R Logical Memory I and II (38)	WAIS III Vocabulary (37)
WAIS-R Visual Reproduction I and II (38)	WAIS III Similarities(37)
Rey Auditory Verbal Learning Test (39)	McKenna Graded Naming Test (40)
Word-pair and single-word recognition (41)	Controlled Oral Word Association Test (42)
<b>Perceptual motor function</b>	
Grooved Pegboard Test (43).	
WIAS III Block design (37)	



Table 2: Demographic and clinical variables

	HIV-1 positive		HIV-1 seronegative	
	Older	Young	Older	Young
Sample size	15	15	16	9
Age	62.5 (5.5)	39.7 (4.0)	59.4 (6.5)	34.2 (5.0)
<b>IQ</b>				
NART	117.14 (6.50)	112.93 (9.27)	118.86 (6.50)	117.67 (6.67)
WAIS-III FSIQ	119.00 (13.35)	118.27 (8.54)	125.06 (9.21)	121.89 (14.79)
<b>Mood</b>				
Depression	6.40 (6.22)	5.53 (4.60)	5.25 (3.36)	3.22 (3.23)
$\Delta$ Depression <sup>a</sup>	-2.00 (5.26)	-1.07 (5.44)	-1.19 (3.14)	-0.38 (2.00)
Anxiety	6.80 (5.26)	4.13 (6.16)	3.25 (3.75)	3.56 (2.46)
$\Delta$ Anxiety <sup>a</sup>	-0.73 (5.47)	-0.60 (6.83)	1.31 (7.07)	-1.13 (1.55)
POMS tension	4.36 (3.93)	2.85 (2.15)	3.72 (2.52)	3.15 (5.34)
POMS depression	1.79 (2.49)	3.00 (4.36)	1.00 (1.69)	2.86 (5.98)
POMS anger	0.64 (1.60)	1.85 (1.86)	1.20 (1.32)	0.71 (1.89)
POMS vigour	19.79 (9.07)	15.07 (5.87)	18.40 (4.42)	17.43 (5.59)
POMS fatigue	3.21 (3.29)	3.84 (5.53)	3.20 (3.76)	2.57 (3.64)
POMS confusion	3.29 (2.13)	3.92 (3.14)	3.27 (2.19)	3.57 (2.15)
PRMQ prospective <sup>b</sup>	50.67 (7.84)	52.80 (8.55)	54.50 (7.36)	60.00 (10.24)
PRMQ retrospective <sup>b</sup>	52.60 (7.91)	57.27 (7.79)	57.50 (6.26)	62.11 (7.42)
<b>HIV variables</b>				
CD4 cells/ mm <sup>3</sup>	711.92 (278.91)	771.47 (352.53)	-	-
Nadir CD4 cells/ mm <sup>3</sup>	183.20 (101.75)	167.15 (96.40)	-	-
Years since diagnosis	16.67 (6.59)	12.40 (5.22)	-	-
Years HAART treatment	12.53 (3.68)	8.60 (2.87)	-	-

Notes: PRMQ=Prospective and retrospective memory questionnaire; POMS=Profile of mood states. <sup>a</sup> baseline – follow-up, <sup>b</sup> t-scores.

Table 3: Hierarchical regression analysis predicting change in global cognitive performance from change in DTI metrics.

	<u>FA Frontal</u>		<u>MD Frontal</u>		<u>FA CC Body</u>		<u>MD CC Body</u>		<u>FA CC Genu</u>		<u>MD CC Genu</u>		<u>FA CC Splenium</u>		<u>MD CC Splenium</u>	
	$\beta$	$\Delta r^2$	$B$	$\Delta r^2$	$\beta$	$\Delta r^2$	$\beta$	$\Delta r^2$	$\beta$	$\Delta r^2$	$\beta$	$\Delta r^2$	$\beta$	$\Delta r^2$	$\beta$	$\Delta r^2$
Step 2																
HIV	-.374**		-.346**		-.366**		-.377**		-.388**		-.370**		-.241*		-.353*	
DTI metric	.400**	.264**	-.368*	.222**	.452**	.318**	-.502**	.316**	.356**	.233**	-.332*	.213**	.445**	.285**	-.313*	.203**
Step 3																
HIV x DTI	.351*	.062*	-.512**	.110**	.178	.006	-.681**	.148**	.542**	.123**	-.512**	.137**	.496*	.061*	-.613**	.123**

Note: Step 1  $\Delta r^2 = .140$ ,  $p = .083$ ; Age  $\beta = -.278$ ,  $p = .059$ ; NART error score,  $\beta = -.328$ ,  $p = .038$ ; Time difference,  $\beta = .088$ ,  $p = .565$ .

DTI = diffusion tensor imaging; FA = fractional anisotropy; MD = mean diffusivity; CC = corpus callosum.

**Figure Captions:**

Figure 1: Mean (standard error) change in z-score for each cognitive domain.

*Notes:* Change scores were generated using baseline minus follow-up. Negative values therefore represent a decline in performance whilst positive values represent an improvement. (1) Main effect of HIV status; (2) Main effect of age group; (3) HIV by Age Group interaction ( $p < .05$ ).

Figure 2: The influence of HIV status on change in mean diffusivity (MD).

*Notes:* Regions in which the HIV group showed a greater increase in MD (red-yellow) than the seronegative controls. This includes the genu and splenium of the corpus callosum, right posterior corona radiata, and right posterior thalamic radiation.

Figure 3: The influence of age on change in mean diffusivity (MD) and fractional anisotropy (FA)

*Notes:* Regions in which older participants show a greater decrease in FA (blue) and greater increase in MD (red-yellow) than younger participants. This includes change in FA in the right anterior corona radiata, right anterior limb of the internal capsule, and the right genu and splenium of the corpus callosum and change in MD in widespread regions.

Figure 1:




Figure 2: The influence of HIV status on change in mean diffusivity (MD).




Figure 3: The influence of age on change in mean diffusivity (MD) and fractional anisotropy (FA)

